ADOC.PA Stock - Adocia S.A.
Unlock GoAI Insights for ADOC.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.32M | $2.15M | $11.45M | $1.44M | $841,000 |
| Gross Profit | $-9,830,000 | $1.39M | $9.61M | $180,000 | $-616,000 |
| Gross Margin | -105.5% | 64.4% | 83.9% | 12.5% | -73.2% |
| Operating Income | $-7,404,000 | $-14,244,000 | $-1,697,000 | $-19,365,000 | $-21,148,000 |
| Net Income | $-9,321,000 | $-21,162,000 | $-6,901,000 | $-22,754,000 | $-23,324,000 |
| Net Margin | -100.0% | -984.3% | -60.3% | -1575.8% | -2773.4% |
| EPS | $-0.60 | $-1.91 | $-0.86 | $-3.22 | $-3.34 |
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.
Visit WebsiteEarnings History & Surprises
ADOC.PAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 15, 2026 | — | — | — | — |
Q3 2025 | Sep 25, 2025 | $-0.48 | $-0.60 | -25.7% | ✗ MISS |
Q2 2025 | Apr 17, 2025 | — | $-0.02 | — | — |
Q4 2024 | Oct 30, 2024 | — | $-0.62 | — | — |
Q2 2024 | Apr 24, 2024 | $2.29 | $-0.88 | -138.6% | ✗ MISS |
Q4 2023 | Oct 25, 2023 | $-1.92 | $-1.03 | +46.5% | ✓ BEAT |
Q2 2023 | Apr 25, 2023 | $-2.16 | $-1.28 | +40.6% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | — | $0.55 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-1.71 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-2.00 | — | — |
Q4 2020 | Dec 31, 2020 | $0.21 | $-1.63 | -877.4% | ✗ MISS |
Q2 2020 | Jun 30, 2020 | — | $-1.71 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.81 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-1.87 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.44 | — | — |
Q2 2018 | Jun 30, 2018 | — | $1.43 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-2.27 | — | — |
Q2 2017 | Jun 30, 2017 | — | $0.97 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.54 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.61 | — | — |
Latest News
Frequently Asked Questions about ADOC.PA
What is ADOC.PA's current stock price?
What is the analyst price target for ADOC.PA?
What sector is Adocia S.A. in?
What is ADOC.PA's market cap?
Does ADOC.PA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ADOC.PA for comparison